EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling

Lin Chen, Dongbei Li, Xiaoli Guo, Cheng Cheng, Xudong Wei

Frontiers in Bioscience-Landmark · 06.09.2023 · 28 (9)

DOI: 10.31083/j.fbl2809195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 06.09.2023. Verfasst von Lin Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008 Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Henan Medical Science and Technology Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute myeloid leukemia (AML) is a recurrence-prone hematologic malignancy. The advent of molecularly targeted therapies provides new opportunities to enhance the effectiveness of AML treatments. Venetoclax, a selective inhibitor of the anti-apoptotic protein Bcl-2, has shown promising results; however, resistance often arises due to elevated expression of the Mcl-1 protein, among other factors. Overcoming this resistance to improve therapeutic outcomes is a pressing issue that requires further investigation. Studies have demonstrated that oridonin, by inhibiting AKT signaling that regulates Mcl-1 expression, can effectively suppress tumor cell growth. This study aims to investigate whether oridonin can synergistically enhance the anti-leukemic effects of venetoclax and explore the underlying mechanisms behind this effect.

Methods

In vitro experiments were performed to evaluate the effects of the combination of oridonin and venetoclax on AML cell proliferation, apoptosis, cell cycle distribution, and mitochondrial membrane potential. Transcriptome sequencing was used to elucidate the molecular mechanisms underlying the synergistic induction of AML cell apoptosis by the combination therapy. Western blotting and reverse transcription quantitative polymerase chain reaction (RT-qPCR) techniques were used to validate the findings. Additionally, an AML mouse model was established to observe the synergistic anti-AML effects of venetoclax combined with oridonin in vivo.

Results

Both venetoclax and oridonin individually exhibited inhibitory effects on AML cell proliferation, resulted in cell cycle arrest, and induced cell apoptosis. Moreover, combination of the two drugs resulted in a synergistic effect. We also observed that oridonin inhibited AKT phosphorylation, upregulated the expression of Bim and Bax proteins, facilitated Mcl-1 degradation, and enhanced the apoptotic effects of venetoclax in AML cells. Finally, in vivo experiments demonstrated that the combination of oridonin and venetoclax effectively inhibited the growth of AML xenograft tumors in mice and prolonged the survival time of tumor-bearing mice.

Conclusions

Oridonin and venetoclax synergistically promote AML cell apoptosis by inhibiting AKT signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteProto-Oncogene Proteins c-aktAnimalsHumansMiceApoptosisCell Line, TumorMyeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2Diterpenes, KauraneSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

AKT signaling pathwayacute myeloid leukemia (AML)apoptosisoridoninvenetoclax

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2oridoninDiterpenes, KauranevenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Hematology Department, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008 Zhengzhou, Henan, China.
  • Central Laboratory, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008 Zhengzhou, Henan, China.

Förderung

  • Henan Medical Science and Technology Research Project

Zitieren

APA

Chen, L., Li, D., Guo, X., Cheng, C., & Wei, X. (2023). Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling. Frontiers in Bioscience-Landmark, 28(9). https://doi.org/10.31083/j.fbl2809195

Vancouver

Chen L, Li D, Guo X, Cheng C, Wei X. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling. Frontiers in Bioscience-Landmark. 2023;28(9). doi:10.31083/j.fbl2809195

BibTeX
@article{Chen2023,
  author = {Chen, Lin and Li, Dongbei and Guo, Xiaoli and Cheng, Cheng and Wei, Xudong},
  title = {Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2023},
  volume = {28},
  number = {9},
  doi = {10.31083/j.fbl2809195}
}
Kostenlos starten →